IN2015DN01361A - - Google Patents
Info
- Publication number
- IN2015DN01361A IN2015DN01361A IN1361DEN2015A IN2015DN01361A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A IN 1361DEN2015 A IN1361DEN2015 A IN 1361DEN2015A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- fusion proteins
- constant regions
- incorporating
- igg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679045P | 2012-08-02 | 2012-08-02 | |
| US201361767724P | 2013-02-21 | 2013-02-21 | |
| PCT/US2013/053086 WO2014022592A1 (en) | 2012-08-02 | 2013-07-31 | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01361A true IN2015DN01361A (da) | 2015-07-03 |
Family
ID=50025683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1361DEN2015 IN2015DN01361A (da) | 2012-08-02 | 2013-07-31 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9540442B2 (da) |
| EP (1) | EP2880057A4 (da) |
| JP (1) | JP2015524821A (da) |
| CN (1) | CN104684928A (da) |
| CA (1) | CA2879814A1 (da) |
| IN (1) | IN2015DN01361A (da) |
| WO (1) | WO2014022592A1 (da) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
| AU2008282496B2 (en) | 2007-07-27 | 2013-04-04 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| JP2015524821A (ja) | 2012-08-02 | 2015-08-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質 |
| CA2939201A1 (en) * | 2014-03-05 | 2015-09-11 | Ucb Biopharma Sprl | Multimeric fc proteins |
| MX2016010951A (es) | 2014-03-05 | 2016-11-29 | Ucb Biopharma Sprl | Proteinas de fc multimericas. |
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| SI3148579T1 (sl) | 2014-05-28 | 2021-07-30 | Agenus Inc. | Proti GITR antitelesa in postopki z njihovo uporabo |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| PL3235830T3 (pl) * | 2014-12-19 | 2020-12-14 | Jiangsu Hengrui Medicine Co., Ltd. | Kompleks białkowy interleukiny 15 i jego zastosowanie |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| EP3957738A1 (en) * | 2015-03-04 | 2022-02-23 | IGM Biosciences, Inc. | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| KR20180002653A (ko) | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법 |
| CN107847591B (zh) * | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| EP3355913B1 (en) | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| CN109195626B (zh) | 2015-10-30 | 2022-09-13 | 银河生物技术有限责任公司 | 结合死亡受体4和死亡受体5的抗体 |
| TWI727380B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| TWI812873B (zh) * | 2015-11-30 | 2023-08-21 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| KR20180098671A (ko) | 2016-01-11 | 2018-09-04 | 인히브릭스, 인크. | 다가 및 다중특이적 ox40-결합 융합 단백질 |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| EP3496536A4 (en) * | 2016-07-20 | 2020-02-12 | IGM Biosciences, Inc. | MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF |
| AU2017299608A1 (en) * | 2016-07-20 | 2019-02-07 | Igm Biosciences, Inc. | Multimeric CD137/4-1BB binding molecules and uses thereof |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| US12297272B2 (en) | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| EP3694885A1 (en) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2019241216A1 (en) | 2018-06-14 | 2019-12-19 | Bioatla, Llc | Multi-specific antibody constructs |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| KR102232659B1 (ko) * | 2018-07-16 | 2021-03-26 | 전북대학교 산학협력단 | 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도 |
| WO2020036867A1 (en) | 2018-08-13 | 2020-02-20 | Inhibrx, Inc. | Ox40-binding polypeptides and uses thereof |
| CN120904316A (zh) * | 2018-12-27 | 2025-11-07 | 伊兰科美国公司 | 兽用IgG Fc变体 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| EP3927746A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| JP7737306B2 (ja) | 2019-02-21 | 2025-09-10 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| CN115843312A (zh) | 2020-04-24 | 2023-03-24 | 马伦戈治疗公司 | 结合至t细胞相关癌细胞的多功能性分子及其用途 |
| EP4149627A4 (en) * | 2020-05-14 | 2024-05-29 | The General Hospital Corporation | POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| GB2616354A (en) | 2020-08-26 | 2023-09-06 | Marengo Therapeutics Inc | Methods of detecting TRBC1 or TRBC2 |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| GB2616128A (en) | 2020-08-26 | 2023-08-30 | Marengo Therapeutics Inc | Antibody molecules that bind to NKp30 and uses thereof |
| KR20220029343A (ko) | 2020-08-31 | 2022-03-08 | (주)메디톡스 | 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물 |
| EP4206226A4 (en) * | 2020-08-31 | 2024-10-16 | Medytox Inc. | Anti-vegf hexameric antibody and composition comprising same |
| WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
| EP4330277A4 (en) * | 2021-04-28 | 2025-03-26 | NGM Biopharmaceuticals, Inc. | Multimerization of binding molecules with a variant of the constant region of an antibody |
| CN115724985A (zh) * | 2021-08-27 | 2023-03-03 | 三生国健药业（上海）股份有限公司 | 一种cdc平台抗体 |
| GB202319645D0 (en) * | 2023-12-20 | 2024-01-31 | Kbio Holdings Ltd | Hexameric protein |
| WO2026011013A1 (en) | 2024-07-02 | 2026-01-08 | Epibiologics, Inc. | Binding agents and uses thereof |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020147326A1 (en) * | 1996-06-14 | 2002-10-10 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| US6475749B1 (en) * | 1999-08-11 | 2002-11-05 | The Regents Of The University Of California | Rh hybrid antibody |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| WO2005047327A2 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2008032833A1 (en) * | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
| GB0922209D0 (en) * | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
| EP2760891B1 (en) * | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| JP2015524821A (ja) | 2012-08-02 | 2015-08-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質 |
-
2013
- 2013-07-31 JP JP2015525568A patent/JP2015524821A/ja not_active Withdrawn
- 2013-07-31 EP EP13825409.9A patent/EP2880057A4/en not_active Withdrawn
- 2013-07-31 US US13/956,121 patent/US9540442B2/en active Active
- 2013-07-31 CA CA2879814A patent/CA2879814A1/en active Pending
- 2013-07-31 WO PCT/US2013/053086 patent/WO2014022592A1/en not_active Ceased
- 2013-07-31 CN CN201380041074.3A patent/CN104684928A/zh active Pending
- 2013-07-31 IN IN1361DEN2015 patent/IN2015DN01361A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140037621A1 (en) | 2014-02-06 |
| US9540442B2 (en) | 2017-01-10 |
| EP2880057A1 (en) | 2015-06-10 |
| CN104684928A (zh) | 2015-06-03 |
| CA2879814A1 (en) | 2014-02-06 |
| WO2014022592A1 (en) | 2014-02-06 |
| JP2015524821A (ja) | 2015-08-27 |
| EP2880057A4 (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01361A (da) | ||
| CA2849765C (en) | Hybrid constant regions | |
| MX2010006767A (es) | Anticuerpos de virus de hepatitis c. | |
| TR201815254T4 (tr) | Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| MX386942B (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| NZ706232A (en) | Anti-cd3 antibodies and uses thereof | |
| CY1120412T1 (el) | Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31 | |
| EA201390923A1 (ru) | Модифицированное антитело с улучшенным полупериодом существования | |
| IN2014MN00873A (da) | ||
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| NZ600262A (en) | Anti-her3 antibodies and uses thereof | |
| DK2681244T3 (da) | Cea-antistoffer | |
| NZ578844A (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
| NZ726258A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| NZ597447A (en) | Humanised antibodies to toll-like receptor 2 and uses thereof | |
| PH12014501927A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ591056A (en) | Human cytomegalovirus neutralizing antibodies and use thereof | |
| EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
| EA201490745A1 (ru) | Полипептиды антител, которые вызывают антагонизм cd40l | |
| GB201005064D0 (en) | Biological products | |
| PL1772465T3 (pl) | Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 |